Abeona Therapeutics’ Post

Abeona Therapeutics reposted this

View organization page for Abeona Therapeutics
Abeona Therapeutics

17,444 followers

The FDA has accepted Abeona’s BLA resubmission for prademagene zamikeracel (pz-cel) in recessive dystrophic epidermolysis bullosa (RDEB) with a PDUFA target action date of April 29, 2025. Read about our latest progress here: https://bit.ly/40I4ukY. #SevereDEB #RDEB #AbeonaTherapeutics

Jennifer Miller

Director of Business Development at ProPharma

4mo

Congratulations!!!

Like
Reply
1 Reaction
Luis Maldonado

Director IT Governance Security & Risk Compliance

4mo

Congrats!

Like
Reply
1 Reaction
Mohamed Duklef

Clinical Program Manager-FFS Medicaid | MS student in Experimental and Clinical Pharmacology

4mo

Exciting news!

Like
Reply
1 Reaction
Sylvain Bedard

Founder and CEO of Clin Ops Solutions LLC

4mo

Fantastic!!

Like
Reply
JC Sabo

Director of Commercial Operations, US at Quick International Courier- A Kuehne + Nagel Company

4mo

Extremely exciting news; a massive achievement!

Like
Reply
1 Reaction
Imani Ribadeneyra

Entrepreneur, Strategist, Marketer

4mo

Amazing news!

Like
Reply
1 Reaction
Ohio Life Sciences

4mo

Congratulations!

Like
Reply
1 Reaction
Kimberly Helms

Senior Buyer

4mo

Congrats!

Like
Reply
Bill McGrath

Associate Director, Trade Relations at Ferring Pharmaceuticals

4mo

Well done

Like
Reply
See more comments

To view or add a comment, sign in

Abeona Therapeutics

17,444 followers

View Profile

Explore topics